Pfizer files LP.8.1 COVID Vax
Pfizer Inc. and BioNTech SE announced that they have submitted a regulatory application to the EMA for approval of Comirnaty for the 2025-2026 season, targeting the LP.8.1 strain.
Pfizer Inc. and BioNTech SE announced that they have submitted a regulatory application to the EMA for approval of Comirnaty for the 2025-2026 season, targeting the LP.8.1 strain. The submission follows the recommendation by the EMA’s Emergency Task Force (ETF) to update the Covid-19 vaccine composition for the coming season to target the LP.8.1 strain. Neither company has so far disclosed any information regarding which age groups the updated vaccine will target, nor mentioned if any clinical studies will be conducted for it.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.